<DOC>
	<DOCNO>NCT00524693</DOCNO>
	<brief_summary>There evidence inflammatory mechanism RSV bronchiolitis increase cysteinyl-leukotrienes ( cys-LT ) . Recently , specific cys-LT receptor antagonists - montelukast ( Singulair© ) approve use infant granule sachet , become available . We evaluate effect Singulair© clinical progress cytokine profile acute phase RSV bronchiolitis .</brief_summary>
	<brief_title>Montelukast Acute RSV Bronchiolitis</brief_title>
	<detailed_description />
	<mesh_term>Bronchiolitis</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Age &gt; 4 week &lt; 2 year Duration respiratory symptom &lt; 4 day Signs bronchiolitis : prodromal rhinorrhea cough , follow least two follow sign : chest retraction , tachypnea , wheeze , rale First episode wheeze shortness breath Randomization within 12 hour admission No need steroid treatment ward Informed consent A history asthma symptom previous hospital admission respiratory tract illness ever treat antiasthma medication ( prior current illness ) . Underlying cardiopulmonary disease bronchopulmonary dysplasia , congenital heart disease , immunodeficiency , cystic fibrosis .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Bronchiolitis</keyword>
	<keyword>control clinical trial</keyword>
	<keyword>pediatrics</keyword>
	<keyword>Infants</keyword>
	<keyword>montelukast</keyword>
	<keyword>Respiratory syncytial virus</keyword>
</DOC>